

Reference

I-269

1. Clinical PharmacologyTM Compendium. 2023. Tampa FL: Gold Standard, Inc. Delandistrogene Moxeparvovec.
2. Micromedex DrugDex Compendium[®]. 2023. Delandistrogene Moxeparvovec-rokl.
3. C Zaidman, C Proudman, C McDonald et al. P.129 One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD. *Neuromuscular disorders*. 2022;32:S101.
4. JR Mendell Z Sahenk, KJ Lehman et al. Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: A 4-year update. 27th International Annual Congress of the World Muscle Society, Halifax, Canada.
5. Mendell J, Shieh P, McDonald C et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. *Front. Cell Dev. Biol.* 2023;11:1167762.
6. Mendell J, Sahenk Z, Lehman K et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. *Muscle Nerve*. 2023;1-6.
7. Elevidys (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion. Sarepta Therapeutics, Inc. Cambridge, MA. Revised 6/2023.